shutterstock_123182704

Horizon and Fulcrum Therapeutics form CRISPR collaboration

pharmafile | September 6, 2016 | News story | Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases 

Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform to identify novel targets for regulating gene expression in genetic diseases for which no effective treatments currently exist.

Fulcrum are a US-based firm founded as recently as July 2016 and have chosen Horizon as their preferred CRISPR-based screening platform provider to work on their projects going forward. The partnership is expected to run for between five and seven months.

Horizon will also use its expertise is bioinformatics and cell line libraries to identify novel gene regulation targets for further exploration by Fulcrum, in their attempt to develop next-generation therapies.

Dr Darrin Disley, CEO at Horizon, says: “CRISPR-based screening promises to be a powerful tool for the identification of novel targets and the collaboration with Fulcrum demonstrates the potential for this technology to be used in areas outside of oncology.”

Robert Gould, President and CEO at Fulcrum, comments: “It was natural for Fulcrum to turn to Horizon as a long-term partner. With their deep scientific expertise, and with a broad IP portfolio underpinning their work, we are confident in a productive and exciting collaboration.”

Sean Murray

Related Content

AstraZeneca to acquire Amolyt Pharma for up to $1.05bn

AstraZeneca has announced that it has entered into a definitive agreement under which it will …

SNIPR Biome reports positive findings for first-in-human, CRISPR-based microbial gene therapy

Danish CRISPR-based microbial gene therapy company SNIPR Biome have announced positive interim data from its …

4972850923_170b36c774

Researchers have tested CRISPR gene editing inside a person’s body for the first time

Allergan and Editas Medicine have treated their first patient in a clinical trial with CRISPR …

Latest content